Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].

来源：新浪港股 香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德（02359）86.94万股，每 股作价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为2989.57万股，持股比例为 5.86%。 ...

Summary of Key Points Core Viewpoint - Qatar Investment Authority has reduced its stake in WuXi AppTec (02359) by selling 869,400 shares at a price of HKD 102.7651 per share, totaling approximately HKD 89.344 million, resulting in a new holding of 29,895,700 shares, which represents 5.86% of the company [1]. Group 1 - Qatar Investment Authority sold 869,400 shares of WuXi AppTec on December 5 [1] - The selling price per share was HKD 102.7651, leading to a total transaction value of approximately HKD 89.344 million [1] - After the sale, Qatar Investment Authority's remaining shares in WuXi AppTec amount to 29,895,700, equating to a 5.86% ownership stake [1]

香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德(02359)86.94万股，每股作 价为102.7651港元，总金额约为8934.4万港元。 香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德(02359)86.94万股，每股作 价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为2989.57万股，持股比例为 5.86%。 ...

智通财经APP获悉，香港联交所最新资料显示，12月5日，Qatar Investment Authority减持药明康德 (02359)86.94万股，每股作价为102.7651港元，总金额约为8934.4万港元。减持后最新持股数目为 2989.57万股，持股比例为5.86%。 ...

Group 1 - Pfizer has entered into an exclusive collaboration and licensing agreement with WuXi AppTec [1]

辉瑞与药明康德达成独家合作及许可协议。 ...

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the HKEX Technology 100 Index, marking its first technology-focused stock index for Hong Kong stocks [1][2] Group 1: Index Composition and Criteria - The HKEX Technology 100 Index includes the largest 100 technology companies listed on the Hong Kong Stock Exchange, covering sectors such as artificial intelligence, biotechnology, electric vehicles, information technology, internet, and robotics [1] - Component stocks must meet specific liquidity and R&D growth criteria: an average daily trading volume of at least HKD 20 million over the past six months and either R&D spending exceeding 3% of revenue or revenue growth exceeding 5% over the past two years [1][2] - Notable companies included in the index are Tencent Holdings, Alibaba Group, BYD Company, and Meituan, among others [1] Group 2: Index Calculation and Adjustment - The index uses a free-float market capitalization weighting method, with a maximum weight of 12% for any single component stock [2] - Component stocks will be adjusted biannually in June and December, with data cut-off dates on the last trading day of April and October each year [2] - Stocks with an average daily trading amount below HKD 20 million over the past six months or those ranking in the bottom 10% by trading volume will be excluded [2] Group 3: Market Implications - The index aims to identify technology stocks with market momentum and growth potential, which may enhance the development of related products in the mainland Chinese market [2] - It addresses the strong demand from mainland investors for opportunities in the Hong Kong technology sector, aligning with the investment needs of southbound capital [2]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the Hong Kong Stock Exchange Technology 100 Index, marking its first technology-focused stock index [1] Group 1: Index Composition and Criteria - The Technology 100 Index includes stocks that meet specific liquidity and R&D growth criteria: an average daily trading volume of at least HKD 20 million over the past six months and R&D expenditure accounting for over 3% of revenue or revenue growth exceeding 5% over the past two years [1][2] - Selected companies include major players such as Tencent Holdings, Alibaba Group, CATL, Lenovo Group, Xiaomi Group, BYD, Meituan, SMIC, and WuXi AppTec [1] Group 2: Index Methodology - The index is calculated using a free-float market capitalization weighting method, with a maximum weight of 12% for any single constituent [2] - Constituents will be reviewed and adjusted biannually in June and December, with data cut-off dates on the last trading day of April and October [2] - The index aims to select technology stocks with market interest and growth potential, catering to the demand from mainland investors for technology investment opportunities in the Hong Kong market [2]

Core Viewpoint - Hong Kong Exchanges and Clearing Limited (HKEX) has launched the Hang Seng Tech 100 Index, the first index for Hong Kong stocks, which tracks the performance of the largest 100 technology companies listed on the Hong Kong Stock Exchange [1] Group 1: Index Composition and Criteria - The Hang Seng Tech 100 Index includes companies that meet specific liquidity and growth criteria: a minimum average daily trading volume of HKD 20 million over the past six months and either R&D expenditure accounting for over 3% of revenue or revenue growth exceeding 5% over the past two years [1][2] - Selected companies include major players such as Tencent Holdings, Alibaba Group, BYD Company, and Xiaomi Group, among others [1] - The index covers six innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] Group 2: Index Methodology and Adjustments - The index uses a free-float market capitalization weighting method, with a cap of 12% on the weight of any single constituent [1] - Constituents are reviewed and adjusted biannually, with data cut-off dates at the end of April and October each year [1] Group 3: Liquidity and Fundamental Requirements - The index has strict liquidity and fundamental requirements: securities with an average daily trading amount below HKD 20 million or ranking in the bottom 10% by trading volume will be excluded [2] - Companies with R&D spending below 3% of revenue or revenue growth below 5% over the past two fiscal years will also be excluded, although companies listed under Chapter 18A or 18C may be exempt from these fundamental requirements [2] - This design aims to select technology stocks with market interest and growth potential, facilitating the development of related products in the mainland Chinese market and meeting the demand for technology investments from mainland investors [2]